NATERA - Key Persons
Job Titles:
- Medical Director, Oncology
Job Titles:
- Medical Director, Oncology
Job Titles:
- General Manager
- Medical Director
- GENERAL MANAGER, ONCOLOGY and ECD & CHIEF MEDICAL OFFICER
Alexey Aleshin, MD, general manager of oncology and early cancer detection & chief medical officer, joined Natera in 2017. He has served in many leadership capacities during his tenure at the company including medical director of oncology, vice president of oncology medical affairs and chief medical officer. Prior to Natera, Dr. Aleshin was actively involved as an advisor and consultant at various companies focused on advancing clinical adoption of next generation sequencing technologies. He received his M.D. and M.B.A. from UCLA and later completed his internal medicine residency at Stanford University Medical Center and his hematology/oncology fellowship at Stanford Hospital.
Job Titles:
- Medical Director, Women 's Health
Job Titles:
- Medical Director, Oncology
Job Titles:
- Head of R & D Program Management
Anu Pai leads Natera's R&D Program Office. With more than 25 years of experience in product development and management, Anu joined Natera from Roche Diagnostics where she held various leadership roles in assay development, product and portfolio management, developing and launching PCR-based products for infectious diseases & blood screening, microbiology and cervical Cancer screening. Anu started her career as an R&D scientist working on multiplex PCR Assay for screening HIV, HCV and HBV, she has also managed large scale clinical trials, as well as design control and regulatory processes, having worked on IVD, RUO, IUO and Companion Diagnostics products. Anu holds an M.S in Chemistry from the University of Kentucky.
Job Titles:
- General Manager, Organ Health
Bernie Tobin is responsible for strategy and execution for Natera's organ health products. Mr. Tobin is a 25-year veteran of the healthcare industry with his most recent role serving as President of Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.
Previously, Mr. Tobin held several senior-level positions at Amgen including General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. In addition, he led the global integration of a business development acquisition in over 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. He received his B.S. degree in Public Service and Administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.
Job Titles:
- Senior Vice President
- SVP of CLINICAL & COMMERCIAL OPERATIONS and PORTFOLIO MANAGEMENT
Chitra Kotwaliwale serves as senior vice president of clinical & commercial operations and portfolio management. She joined Natera in 2019 and has held multiple roles across product management and strategy, overseeing product management for the women's health team, managing overall strategic planning and PMO for Engineering/R&D, and coordinating global product strategy. Prior to joining Natera, Chitra served as director of product marketing at Agilent Technologies, where she managed the company's product management team responsible for target enrichment content products for rare diseases and oncology. She previously served as senior product manager of sequencing at Complete Genomics, and prior to that, as a computational biologist at Adaptive Biotechnologies (formerly Squenta, Inc.). Chitra holds a B.A. in biology from the College of Wooster and a Ph.D. in molecular and cell biology from the University of Washington and the Fred Hutchinson Cancer Center. She completed her postdoctoral fellowships at the University of California, Berkeley, which was funded by prestigious fellowships from the Damon Runyon Cancer Research Foundation and Howard Hughes Medical Institute.
Job Titles:
- Chief Legal Officer
- Member of the Executive Management Team
- Secretary
Daniel Rabinowitz is Secretary and Chief Legal Officer of Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and, before that, was also a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management and compliance with US federal and state securities law. He has studied genetics, biochemistry, and molecular biology at Harvard University Extension School and attended courses on the legal and ethical aspects of biotechnology at Harvard Law School. Mr. Rabinowitz completed his B.A. and LL.B. degrees at the University of the Witwatersrand, South Africa, graduating at the top of his law school class, and completed his LL.M. at New York University School of Law with both Rotary Foundation and Fulbright Scholarships. Admitted in New York only.
Job Titles:
- Chief Scientific Officer
- Medical Director
- in 2020 As Chief Scientific Officer
Dr. Eric Evans joined Natera in 2020 as Chief Scientific Officer. Prior to joining Natera, he was co-founder and Chief Scientific Officer of Counsyl for 12 years. In that role, he led R&D and clinical operations for a molecular diagnostics portfolio in women's health and oncology. He has authored papers in reproductive genetics and molecular diagnostics, including journals such as JAMA, Genetics in Medicine, Clinical Chemistry, and Prenatal Diagnosis. He received his B.S. in Biological Sciences from the University of Delaware and his Ph.D. in Genetics from Stanford University. While at Stanford, he was a Stanford Graduate Fellow working on the genetics of aging and the immune system.
Dr. John Ryan joined Natera as its Chief Laboratory Officer in 2023. Dr. Ryan brings more than twenty eight years of operations experience, with expertise in diagnostic laboratory operations, laboratory partnerships, supply chain management, kit manufacturing and customer service. He most recently served as the Senior Vice President of Operations at Myriad Genetics, overseeing its Neuroscience, Women's Health, Oncology and International Operations. Dr. Ryan previously served in various roles at Myriad Genetics including Vice President of Hereditary Cancer Operations, Senior Director of Customer Service and Senior Director of Operations. Prior to his time at Myriad Genetics, Dr. Ryan served in the Armed Forces DNA Identification Lab. He obtained a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz, a Ph.D. in Genetics from Stony Brook University and an Executive MBA from the University of Utah David Eccles School of Business.
Job Titles:
- Co - Founder
- Executive Chairman
- Executive Chairman of the Board
- Founder
- Member of the Executive Management Team
In 2004, my sister gave birth to a son with Down syndrome. He passed away six days after birth. It was a devastating experience for our entire family. I founded Natera because I believe all families deserve access to technologies that offer early detection of genetic disease.
Matthew Rabinowitz, Ph.D. is a co-founder of our company and currently serves as our Executive Chairman. Dr. Rabinowitz served as our Chief Executive Officer from 2005 to January 2019, and served as a member of our board of directors since 2005. He served as Chairman of our board of directors from May 2015 to January 2019, at which time he assumed the role of Executive Chairman. Prior to co-founding our company, Dr. Rabinowitz served from 2000 to 2003 as chief executive officer and from 2003 to 2007 as chief technology officer of Rosum Corporation, a location services technology company. Dr. Rabinowitz served as a consulting professor at Stanford University from 2004 to 2012 and as visiting faculty in the Genetics Department of Harvard University from 2018 to 2019. Dr. Rabinowitz has over 100 patents and publications in signal processing, machine learning, bio-informatics, and high-throughput genetic testing. He received the Scott Helt Memorial Award from the Institute of Electrical and Electronics Engineers and has twice received the Technology Pioneer Award from the World Economic Forum. He currently serves as a member of the board of directors or advisory board of a number of technology companies. Dr. Rabinowitz holds a Bachelor of Science degree in Engineering and Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering, from Stanford University.
Dr. Matthew Rabinowitz is co-founder of Natera and currently serves as the Executive Chairman of the board of directors. He served as Natera's Chief Executive Officer from 2005 to 2018. Prior to co-founding Natera, Dr. Rabinowitz founded Rosum Corporation, a location-systems company that used terrestrial digital television broadcasts to enhance GPS indoors, where he was Chief Executive Officer from 2000 to 2003 and Chief Technology Officer from 2003 to 2006. For this technology, Dr. Rabinowitz received the Scott Helt Memorial Award from the IEEE. From 1998 to 2000, he served as co-founder and Chief Scientist of Panop.com Inc., a technology company for personalized online merchandising that was sold after roughly two years for $100M. Dr. Rabinowitz served as a consulting professor at Stanford University for 8 years and in 2018, began as Visiting Faculty in the Genetics Department of Harvard University. He has served as Principal Investigator on six research grants from the National Institutes of Health and has authored over 100 patents and academic papers, including journals such as IEEE Transactions, Bioinformatics, Science, Nature, JAMA Oncology, Journal of Clinical Oncology, Human Reproduction, Molecular Human Reproduction, Fertility and Sterility, Obstetrics and Gynecology, Ultrasound in Obstetrics and Gynecology, and Genome Medicine. Two companies that he founded received the World Economic Forum Technology Pioneer award, awarded each year to 20 companies worldwide. He is on the board of the foundation of the American College of Medical Genetics and is a board member, advisor, and angel investor for multiple companies in biotechnology, diagnostics, gene editing, machine learning, communications, and cleantech. Dr. Rabinowitz completed one year at the University of the Witwatersrand, South Africa, and holds a Bachelor of Science degree in Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering with a minor in Aeronautics and Astronautics, all from Stanford University.
Job Titles:
- Medical Director
- General Manager, Women 's Health
Dr. Ramesh Hariharan is responsible for strategy and execution of Natera's women's health business. Dr. Hariharan's career of 24 years spans a range of subspecialties, including basic research, strategic management consulting, and marketing. At GE's Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women's Health, and Vaccines at Novartis, Abbott/AbbVie and Biotheranostics. At Biotheranostics, he drove the commercial turnaround of Breast Cancer Index, which resulted in a successful financial exit for the parent company. After Biotheranostics, Dr. Hariharan joined Natera to head the Marketing & Medical Education function and 2.5 yrs later transitioned to lead the Women's Health business. He received a bachelor's degree in Chemical Engineering from IIT Bombay, a Ph.D. in Chemical Engineering from Princeton University, and an MBA from MIT Sloan School of Management
Job Titles:
- Assistant Professor
- Director
- Member of the Audit Committee
- Member of Our Board of Directors
Gail Marcus has served as a member of our board of directors since March 2017. Dr. Marcus is currently an Assistant Professor and Executive in Residence at the Massachusetts College of Pharmacy and Health Sciences. Prior to academia, Dr. Marcus was a healthcare executive across a diverse portfolio of healthcare organizations in the US and UK, including Cigna, UnitedHealthcare Group Inc., CVS/Caremark, and Caris Diagnostics of Caris Life Sciences. In 2014, she was selected as one of the top 100 women executives in Massachusetts. Dr. Marcus currently serves on the boards of directors of another public company, a private company and a non-profit organization, and sits on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests. Dr. Marcus holds a Doctorate of Health Administration from the Medical University of South Carolina. She received a B.A. in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School Of Engineering and a M.B.A. from the Wharton School of the University of Pennsylvania.
Job Titles:
- Medical Director, Oncology
Job Titles:
- Director
- Member of the Audit Committee
- Member of the Compensation Committee
Herm Rosenman served as our Chief Financial Officer from February 2014 to January 2017, and has served as a member of our board of directors since February 2017. Prior to joining our company, he held the position of Senior Vice President-Finance and Chief Financial Officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood, from June 2001 to April 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Prior to joining Gen-Probe, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial stage diagnostics company, since2013. Mr. Rosenman served on the board of directors of Medistem, Inc., a stem cell therapy company, from 2013 to2014; ARYx Therapeutics Inc., a private drug discovery and development company, from 2006 to 2009; Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chairman of the Audit Committee, from 2003 to 2007. He has also served on the board of directors of a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.
Job Titles:
- Medical Director, Organ Transplant
As Senior Vice President of Laboratory Affairs & Quality, and Natera's corporate CLIA Laboratory Director, Dr. Keen-Kim is responsible for the overall operation and administration of the clinical laboratories, as well as Natera's Quality culture. Since joining Natera in 2018, Dr. Keen-Kim built the genetic variant classification and curation processes, has grown data analysis and clinical reporting operations 4-fold, and provides daily quality oversight and risk management in oncology, women's health, and transplant diagnostics. With expertise in cell-free DNA, Next Generation Sequencing, and automation technologies, Dr. Keen-Kim earned a bachelor's degree from Carnegie Mellon University, a Ph.D. from MIT, completed her fellowship at UCLA, and currently serves as an Adjunct Clinical Professor at Stanford University School of Medicine. She is licensed by California and New York to direct medical laboratories and maintains three HHS-approved board certifications. Dr. Keen-Kim is a mentor and champion for women leaders and is passionate about staff training and development to create growth opportunities for the next generation.
Job Titles:
- Director
- Member of the Audit Committee
- Member of the Compensation Committee
- General Partner at Sofinnova Ventures
- Member of Our Board of Directors
James I. Healy has served as a member of our board of directors since November 2014. Dr. Healy has been a General Partner at Sofinnova Ventures, a venture capital firm, since 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories), a research-based pharmaceutical company and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently the Chairman of CinCor (CINC) and of Y-mAbs (YMAB), a member of the board of directors for Atsena, Karuna (KRTX), the lead independent director of Bolt (BOLT) and a board observer at Visen. Previously, Dr. Healy served as a board member of Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammation and autoimmune diseases, from 2006 to 2014; Durata Therapeutics, Inc., a pharmaceutical company focused on infectious and acute diseases, from 2009 to 2013; InterMune, Inc., a biotechnology company focused on orphan fibrotic pulmonary disease, from 1999 to 2014; KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of monoclonal antibody therapeutics, from 2001 to 2014; Hyperion Therapeutics, Inc., a commercial-stage orphan disease company, from 2007 to 2015 and several private companies. Dr. Healy holds an M.D. and Ph.D. in Immunology from Stanford University School of Medicine and performed neuroscience research at the University of Virginia School of Medicine. Dr. Healy holds a Bachelors of Arts in Molecular Biology and Scandinavian Studies from the University of California at Berkeley.
Job Titles:
- Medical Director Women 's Health
Job Titles:
- Medical Director
- Chief Compliance and Privacy Officer
Jerry Diffley joined Natera in August of 2017 as its Chief Compliance and Privacy Officer. Mr. Diffley is a seasoned laboratory executive with extensive experience in U.S. and international laboratory compliance, privacy, billing and laboratory operations.
Prior to joining Natera, Mr. Diffley worked at Quest Diagnostics for over 23 years in a variety of operational positions and more recently in its Legal Compliance function. Mr. Diffley holds a B.S. in Education from SUNY Plattsburgh and a Master's degree in Business and Healthcare Administration from Stony Brook University.
Job Titles:
- CHIEF BUSINESS OFFICER
- Medical Director
- PRESIDENT
John Fesko, president, chief business officer, joined Natera in 2014. He leads company-wide efforts across multiple functions and programs, including collaborations with payors, government affairs, business development, market development, pharmaceutical services, patient experience, communications, marketing, and international commercial operations and strategy. Prior to Natera, John worked at Roche, Novartis Pharma AG, MPM Capital and InVivoScribe. He holds an M.B.A. from M.I.T. and a B.S. in biochemistry and economics from the University of Notre Dame.
Job Titles:
- Co - Founder
- Director
- Member of Our Board of Directors
Jonathan Sheena is a co-founder of our company. Mr. Sheena has served as a member of our board of directors since 2007, and served as our Chief Technology Officer from 2007 to December 2020. In 1999, Mr. Sheena co-founded PhoneSpots, Inc. (formerly PocketThis, Inc.), a mobile technology company serving mobile carriers worldwide. From June1999 to December 2007, Mr. Sheena held various roles at PhoneSpots, Inc. including vice president of product management and chief technology officer. Mr. Sheena holds a Bachelor of Science in Electrical Engineering and Computer Science, and a Master of Engineering in Electrical Engineering and Computer Science, from the Massachusetts Institute of Technology.
Job Titles:
- Assoc. Medical Director, Oncology
Job Titles:
- Medical Director, Heart Transplant
Job Titles:
- Chief Financial Officer
- Medical Director
- Member of the Executive Management Team
Mike Brophy is Natera's CFO. He joined Natera in 2015 serving as Natera's Senior Vice President of Finance and Investor Relations, and prior to that as Vice President of Corporate Development and Investor Relations. Prior to joining Natera, he served as an executive director and as a vice president in the investment banking division of Morgan Stanley, where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds a master's degree in business administration from the University of California, Los Angeles, and a Bachelor of Science degree in economics from the United States Air Force Academy. His military career included leading a multi-agency, 10-person team on a $1.4 billion contract to modernize 10 remote satellite tracking stations worldwide.
Job Titles:
- Chief Medical Officer, Oncology
Job Titles:
- Chief Accounting Officer
- Medical Director
Olesya A. Anisimova, CPA, has served in public accounting and industry for over 15 years. During her career, Olesya's primary focus was on manufacturing and biotechnology industries. Olesya came from Ernst & Young and started at Natera in February 2015 as an Assistant Controller and was subsequently promoted to Senior Director of Finance & Corporate Controller. Olesya's role had evolved into VP of Finance and Senior VP of Finance throughout her career at Natera. Since January 2022, Olesya has been serving Natera as the Chief Accounting Officer. Since joining the company in early 2015, Olesya has played a crucial role in the company's success. She successfully filed Natera's IPO with the accounting and finance team and is responsible for Natera's annual and quarterly SEC filings. She has managed a broad range of responsibilities including driving improvements in various operations, performing SEC filings, and SOX compliance controls. She was recently leading on the Company's new ERP Implementation as well. Olesya continues her role as Chief Accounting Officer for Natera, as well as working closely with the CFO and FPA Team on strategic decisions for company operations.
Job Titles:
- Medical Director, Organ Health
Job Titles:
- Chief Technology Officer
- Medical Director
Rishi Kacker serves as Natera's Chief Technology Officer, bringing 20-years of experience in software, genetics, and health tech entrepreneurship. At Natera he is responsible for leading a team including product, UX, software engineering and IT with the mission to expand access to genetic testing for millions each year through innovations/transformation in the patient and provider experience. Additionally, the team has launched a massive clinico-genomic data and research platform being used to accelerate our knowledge of genetic disease. Prior to Natera, Mr. Kacker was the Chief Technology Officer at Myriad Genetics and co-founder and SVP of Technology at Counsyl (acquired by Myriad Genetics). He started his career as co-founder of Voltage Security, a data security and enterprise software business that was acquired by HP Enterprise. Mr. Kacker holds a B.S. degree in computer science from Stanford University.
Job Titles:
- Chief Operating Officer
- Medical Director
- Member of the Executive Management Team
Robert Schueren is an accomplished industry veteran with extensive molecular diagnostics, genomics, and pharma experience. Mr. Schueren has enjoyed an expansive 30-year career and has been a driving force behind rapid business growth at both start-up and large biotech companies. Most recently, he was CEO of IntegenX Inc., playing a critical role in the growth and success of the company, and ultimate acquisition by Thermo Fisher Scientific, as well as successfully leading a lobbying effort to pass the Rapid DNA Act of 2017. Mr. Schueren previously held executive leadership roles including GM of Genomics at Agilent Technologies, Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc. He formerly held leadership and commercial roles at Arcturus Bioscience, Accumetrics, Biosite Diagnostics, Gen-Probe, and Abbott Labs. Mr. Schueren received a BS in Pharmacy from Temple University.
Job Titles:
- Director
- Member of Nominating, Corporate Governance and Compliance Committee
- Member of Our Board of Directors
Roelof F. Botha has served as a member of our board of directors since 2007. Mr. Botha has been with Sequoia Capital, a venture capital firm, since 2003, and has been a Managing Member of Sequoia Capital Operations, LLC since 2007.From 2000 to 2003, Mr. Botha served in a number of roles at PayPal, Inc., most recently as the Chief Financial Officer. From 1996 to 1998, Mr. Botha served as a management consultant for McKinsey & Company, a management consulting firm. Mr. Botha currently serves on the board of directors of Square, Inc. (NYSE: SQ), a provider of payments, financial and marketing services; MongoDB, Inc. (Nasdaq: MDB), a document oriented database program developer; Eventbrite, Inc. (NYSE: EB), an event management and ticketing platform; Unity, Inc. (NYSE: U), a 3D and VR content development platform, and a number of private companies. Mr. Botha holds a Bachelor of Science in Actuarial Science, Economics, and Statistics from the University of Cape Town and an M.B.A. from Stanford University.
Job Titles:
- Director
- Member of the Audit Committee
- Member of the Compensation Committee
- Member of Our Board of Directors
Rowan Chapman has served as a member of our board of directors since August 2019. Dr. Chapman is a founder, investor, and active independent board member of various companies. She most recently held senior roles as Head of Johnson & Johnson Innovation, Western North America, Australia and New Zealand, and as Head of Precision Diagnostics at GE Healthcare Life Sciences, Managing Director of New Business Creation, and Head of Healthcare Investing at GE Ventures. Prior to that, she held operational roles in early and growth-stage startups and was a partner at Mohr Davidow Ventures for over 11 years, gaining extensive experience as a board member and board advisor for a wide variety of tech and data-enabled companies. Dr. Chapman holds a Bachelor of Arts degree in Biochemistry and a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the University of Cambridge, United Kingdom.
Job Titles:
- Director
- Chief Medical Officer at Merck
- Member of Our Board of Directors
Roy Baynes has served as a member of our board of directors since July 2018. Dr. Baynes is Chief Medical Officer at Merck, and Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories. Dr. Baynes was previously Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, and also served as Vice President of Global Clinical Development and Therapeutic Area Head for Hematology/Oncology at Amgen. Dr. Baynes has had a long and distinguished career in the hematology, oncology, and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching, and administration. He is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research, and has authored about 150 publications. Before joining industry in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center. Dr. Baynes graduated as a medical doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand in Johannesburg, South Africa.
Job Titles:
- Director
- Member of the Compensation Committee
- Healthcare Executive
Ruth E. Williams-Brinkley joined our board of directors in March 2023. Williams-Brinkley is a veteran healthcare executive who currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), overseeing the company's care delivery and health plan operations in Washington, D.C., suburban Maryland, Baltimore, and Northern Virginia. She was previously president of Kaiser Foundation Health Plan and Hospitals of the Northwest, CEO of KentuckyOne Health, president and CEO of Carondelet Health Network in Tucson, Arizona, and president and CEO of Memorial Healthcare System in Chattanooga, Tennessee. Williams-Brinkley serves on the boards of Travere Therapeutics, DePaul University, the Greater Washington Board of Trade, and the Northern Virginia Trade of Commerce. She holds both a bachelor's degree and Master of Science degree in nursing from DePaul University.
Job Titles:
- Medical Director, International
Job Titles:
- Chief Medical Officer, Organ Health
Job Titles:
- Vice President of Medical Affairs
Ms. Parmar is vice president of medical affairs for women's health and head of clinical services at Natera. She is a board-certified genetic counselor specializing in prenatal diagnosis and screening. Sheetal received her BA in Molecular and Cell Biology from UC Berkeley and her MS in Genetic Counseling from the University of Cincinnati, where she was a Albert C. Yates Scholar and Fellow. She joined Natera after working 11 years as the lead prenatal genetic counselor at a high-risk prenatal diagnosis clinic and cytogenetic laboratory. She has served on the Board of Directors for the National Society of Genetic Counselors (NSGC) and is currently a site visitor for the Accreditation Council of Genetic Counseling (ACGC). In 2020, Sheetal accepted the Leading Women Entrepreneur Force for Change Illuminator award for her leadership and contributions to Natera's positive impact on the lives of others during the COVID-19 pandemic. Sheetal has held a number of positions at Natera, including director of medical education director and senior director of clinical genetic services. She enjoys building new products and traveling across the US and internationally to provide clinical education on Natera's products.
Job Titles:
- President
- PRESIDENT, CLINICAL DIAGNOSTICS
Solomon Moshkevich serves as president, clinical diagnostics, where he oversees productization, clinical validation, commercialization, and quality across the company. Since joining Natera in 2011, Solomon has built and led multiple teams including global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, business development, international sales, program management and portfolio strategy; and he has played a leading role in the development, clinical validation and commercial success of all Natera's cell-free DNA products including Panorama, Prospera, and Signatera. Most recently, Solomon served as general manager of oncology for the company, overseeing a period of tremendous growth and leading the company's efforts to achieve Medicare coverage for Signatera across multiple cancer types. Solomon began his career as a consultant with Bain & Company in New York before joining the private equity investment team at Parthenon Capital in Boston; and he currently serves on the Board of Directors for the Ronald McDonald House Charities of the Bay Area. He graduated from Columbia University summa cum laude with a B.A. in Economics and Mathematics, and he holds an M.B.A. from Stanford University.
Job Titles:
- Chief Executive Officer
- Director
- Medical Director
- Member of the Executive Management Team
Steve Chapman is Natera's Chief Executive Officer and serves on the company's board of directors. During his tenure, he has held a number of leadership roles including Chief Operating Officer. As COO, he led the company's entry into the highly competitive non-invasive prenatal testing market, in which the company's Panorama® test became the market leader despite being fourth to market. Mr. Chapman was appointed CEO in January 2019 and has been instrumental in extending Natera's core technology to address new organ health and oncology markets. This includes driving rapid growth for the Prospera™ transplant assessment test, launching the RenasightTM test which screens for genetic causes of chronic kidney disease, and establishing Natera's leadership in molecular residual disease testing with Signatera.™ Since becoming CEO, Natera has achieved significant year-on-year revenue growth and has consistently outperformed earnings expectations. Prior to joining Natera, Mr. Chapman worked at Genzyme Genetics, where he was credited with delivering record-breaking growth and strategies that changed pregnancy genetic testing. Mr. Chapman began his career as a researcher in the department of human genetics at UCLA designing arrays identifying SNPs associated with multiple sclerosis. He graduated with honors and holds a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA.
Steve Chapman has served as the Company's Chief Executive Officer, and as a director on its board of directors, since January 2019. Previously, Mr. Chapman served as the company's Chief Operating Officer from August 2017 to January 2019, and he held other leadership roles prior to that. Before joining Natera in December 2010, Mr. Chapman worked at Genzyme Genetics Corp., a biotechnology company. Mr. Chapman holds a Bachelor of Science in Microbiology, Immunology and Molecular Genetics from University of California, Los Angeles.
Job Titles:
- Medical Director, Women 's Health